2020-08-26 23:30
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE...
2020-08-26 17:34
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE...
2020-08-26 17:30
Biovica today announces that the clinical validation of the blood test DiviTum® TKa has been completed, demonstrating the clinical value of the product. The clinical validation is the final part of Biovica’s application for US market approval...
2020-07-22 08:00
The Board of Directors of Biovica International AB, corporate identity number 556774-6150, hereby convenes the Annual General Meeting on 27 August 2020 at 16:00 in the company's premises at Dag Hammarskjölds väg 54B, Uppsala Science Park...
2020-06-30 08:00
Biovica’s annual report for the fiscal year 2019/2020 is published on our website https://biovica.com/investor-relations/financials/ Contact Anders Rylander, CEO Phone: +46-18-444 48 35 E-mail: anders.rylander@biovica.com Cecilia Driving, EVP CFO/HR/IR...
2020-06-17 08:00
Biovica, active in cancer diagnostics, today announced that the analytical validation of the blood test DiviTum has been completed. The validation aims to verify technical and precision requirements defined in consultation with the US Food and Drug Administration...
2020-06-05 08:00
Preparations for the launch of DiviTum® have started Significant events during the fourth quarter Significant events after the end of the period CEO’s comments Biovica has had yet another eventful quarter. We have focused our efforts on the...
2020-05-22 09:45
Uppsala, Sweden, May 22, 2020. The ASCO educational book 2020 highlights DiviTum® as a solution to address unmet needs within monitoring treatment effect of CDK4/6 inhibitors. The authors Erik S. Knudsen, PhD at Roswell Park Cancer Center, Geoffrey...
2020-05-11 08:15
Uppsala, Sweden, May 11, 2020. The scientific journals British Journal of Cancer, a Nature journal, and Biomarkers in Medicine have published articles on DiviTum® results and TK activity as a biomarker for evaluating efficacy of CDK4/6 inhibitors...
2020-05-11 08:00
Uppsala, Sweden, May 11, 2020. Biovica, active in cancer diagnostics, hosts today its virtual capital market day at 14.00-16.00. The purpose is to provide an update on Biovica's market launch strategy and goals. Biovica is also providing a market...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects